Literature DB >> 22293840

Pulmonary drug delivery: novel pharmaceutical technologies breathe new life into the lungs.

Basavaraj K Nanjwade1, Sagar A Adichwal, Kishori R Gaikwad, Kemy A Parikh, F V Manvi.   

Abstract

Pulmonary drug delivery is a developing technology in which medication is inhaled through the lungs and enters the bloodstream through the alveolar epithelium. Pulmonary drug delivery provides a noninvasive, alternative method to subcutaneous injection, and also intravenous injection. The delivery device plays a major role in the efficiency of pulmonary delivery, and great strides have been made in the development of new devices in recent years. The devices most commonly used for respiratory delivery, including nebulizers, metered-dose inhalers, and dry powder inhalers, can all be adapted for use with protein/peptide drugs. The choice of device will depend on the drug, the formulation, the site of action, and the pathophysiology of the lungs. While a great deal of recent research has focused on the development of novel devices, attention must now be paid to the formulation of these macromolecular drugs. The emphasis in this review will be on targeting of drugs by inhalation using carriers (such as liposomes, microspheres, microparticles, and nanoparticles) and ligands.

Mesh:

Year:  2011        PMID: 22293840     DOI: 10.5731/pdajpst.2011.00704

Source DB:  PubMed          Journal:  PDA J Pharm Sci Technol        ISSN: 1079-7440


  5 in total

Review 1.  Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation.

Authors:  Anil Kumar; Fei Chen; Anbu Mozhi; Xu Zhang; Yuanyuan Zhao; Xiangdong Xue; Yanli Hao; Xiaoning Zhang; Paul C Wang; Xing-Jie Liang
Journal:  Nanoscale       Date:  2013-09-21       Impact factor: 7.790

Review 2.  A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases.

Authors:  Siqin He; Jiajia Gui; Kun Xiong; Meiwan Chen; Huile Gao; Yao Fu
Journal:  J Nanobiotechnology       Date:  2022-03-03       Impact factor: 10.435

3.  Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model.

Authors:  M D Reed; C S Tellez; M J Grimes; M A Picchi; M Tessema; Y S Cheng; T H March; P J Kuehl; S A Belinsky
Journal:  Br J Cancer       Date:  2013-09-17       Impact factor: 7.640

4.  Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model.

Authors:  Philip J Kuehl; Marcie J Grimes; Devon Dubose; Michael Burke; David A Revelli; Andrew P Gigliotti; Steven A Belinsky; Mathewos Tessema
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

Review 5.  Adverse immunological responses against non-viral nanoparticle (NP) delivery systems in the lung.

Authors:  Leonor de Braganca; G John Ferguson; Jose Luis Santos; Jeremy P Derrick
Journal:  J Immunotoxicol       Date:  2021-12       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.